黑料官网

header-logo
GettyImages-609179959-hero
headshot

Binod Dhakal, MD

Associate Professor

view physician profile

Locations

  • Froedtert Hospital
  • Clinical Cancer Center - Froedtert Hospital

Specialties

  • Hematology
  • Medical Oncology

Languages

  • English, Nepali, Hindi

Clinical Cancer Center - Froedtert Hospital

Education

  • MD - Doctor of Medicine

Biography

Binod Dhakal, MD, MS, is Assistant Professor of Medicine, at the 黑料官网, Division of Hematology, specializing in multiple myeloma and plasma cell disorders. He graduated from Manipal College of Medical Sciences, Pokhara Nepal in 2004, completed Internal Medicine Residency at Saint Francis Hospital Evanston Illinois, and a fellowship in hematology/oncology at the 黑料官网, where he also served as a Chief Fellow. Prior to joining the fellowship, he was Assistant Professor of Medicine at the Medical College in Wisconsin in the Division of General Internal Medicine. He has authored numerous publications, including journal articles, meeting abstracts and book chapters. He has also won several awards during his fellowship which include the American Society of Clinical Oncology (ASCO) Merit Award; 黑料官网 Affiliated Hospitals (黑料官网AH) research award; Central Society for Clinical and Translational Research (CSCTR) best oral abstract and travel trainee award; American Society for Blood and Marrow Transplantation (ASBMT) clinical research training course; and, Outstanding Medical School Teacher award. Additionally, he was the recipient of the Mazie Froedtert Willms and Sue Froedtert Cancer Scholarship, and obtained his Master’s Degree in Clinical and Translational Science.

Research Interests

Dr. Dhakal's current research interests focus on novel drug treatments for patients with multiple myeloma and related plasma cell disorders by designing and conducting early phase clinical trials.

Publications

  • (Galarza Fortuna GM, Peres L, Nazarenko E, De Menezes Silva Corraes A, Hovanky VN, Shune L, McGuirk J, De Avilla G, Khouri J, Dima D, Gaballa M, Dhakal B, Forsberg P, Godara A, Afrough A, Anderson L, Herr MM, Davis JA, Mann H, Purvey S, Clark W, Htut M, Beitinjaneh A, Pereira DL, Kocoglu MH, Ferreri CJ, Atrash S, Voorhees PM, Rossi A, Shambavi R, Hashmi H, Patel K, Sidana S, Lin Y, Hansen DK, Sborov DW.) Blood Adv. 2025 Dec 09;9(23):6009-6018 PMID: 40875887 08/28/2025

  • (Al Hadidi S, Szabo A, Mohan Lal B, Bag A, Zhen S, Ogunsesan Y, Annyapu E, Dhakal B, Bhutani D, Thanendrarajan S, Zangari M, D'Souza A, Lentzsch S, van Rhee F, Chakraborty R, Schinke C, Mohan M, Shah MR.) Blood Cancer J. 2025 Nov 07;15(1):196 PMID: 41203605 PMCID: PMC12594773 SCOPUS ID: 2-s2.0-105021068508 11/08/2025

  • (Kasomva K, Yadav K, Janz S, Dhakal B, Rao S.) Blood Adv. 2025 Oct 28;9(20):5134-5147 PMID: 40674709 PMCID: PMC12550235 07/17/2025

  • (Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees M, Costello P, Vazquez Martinez M, Pasvolsky O, Wagner C, Davis JA, Castaneda Puglianini O, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo R, Freeman C, Mikkilineni L, Raza S, Anderson LD Jr, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa M, Midha S, Alsina M, Sborov D, Patel K, Lin Y, Ferreri C, Gagelmann N, Kumar A, Hansen D, Cowan A, Costa LJ, Merz M, Sidana S.) Blood. 2025 Oct 23;146(17):2063-2072 PMID: 40749169 SCOPUS ID: 2-s2.0-105014970046 08/01/2025

  • (Shrestha A, Thanendrarajan S, Bag A, Dhakal B, Zangari M, Al-Hadidi S, van Rhee F, D'Souza A, Shah N, Shah MR, Mohan M, Schinke C.) Blood Adv. 2025 Oct 14;9(19):4806-4809 PMID: 40674710 PMCID: PMC12494909 SCOPUS ID: 2-s2.0-105017267704 07/17/2025

  • (Henley EC, Liphart HA, Morris KJ, Awoyinka I, Irwin MR, Costanzo ES, Winston D, D'Souza A, Stolley M, Dhakal B, Mohan M, Pasquini MC, Cole SW, Doerwald ES, Bendis PC, Rentscher KE, Rumble ME, Szabo A, Rao S, Knight JM.) Contemp Clin Trials Commun. 2025 Oct;47:101540 PMID: 40893725 PMCID: PMC12397865 09/02/2025

  • (Touzeau C, Lipe B, Khan AM, Dhakal B, Nair S, He J, Mendes J, Lee S, Lonardi C, Slaughter A, Lendvai N, Schecter JM, Chen D, Zhao M, Yeh TM, Leleu X, Puig N, Dytfeld D, Zamagni E, Weisel K, Karlin L, Delforge M, Corradini P, Mina R, Roeloffzen W, Sidana S.) Adv Ther. 2025 Oct;42(10):5023-5041 PMID: 40768190 PMCID: PMC12474644 SCOPUS ID: 2-s2.0-105012841831 08/06/2025

  • (Yadav K, Mohan M, Wagner C, Chakraborty R, Sborov D, Godara A, McClune B, Schinke C, Dhakal B, D'Souza A, Szabo A, Mohyuddin GR.) Leukemia. 2025 Sep;39(9):2289-2291 PMID: 40670671 SCOPUS ID: 2-s2.0-105011037613 07/17/2025

  • (Vandenboom H, Akhtar O, Szabo A, Narra R, Mohan M, D'Souza A, Pasquini M, Dhakal B.) Haematologica. 2025 Aug 14 PMID: 40820831 08/18/2025

  • (Ailawadhi S, Anderson LD Jr, Dhakal B, Shune L, Sborov DW, Hansen DK.) Clin Lymphoma Myeloma Leuk. 2025 Aug 07 PMID: 40885679 08/31/2025

  • (Dhakal B, Einsele H, Schecter JM, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Nair S, Varghese NE, He J, Kharat A, Lee S, Cost P, Potluri R, Koneru M, Patel N, Florendo E, Rodriguez-Otero P, Yong K.) Cancer Med. 2025 Aug;14(15):e71093 PMID: 40719208 PMCID: PMC12301936 SCOPUS ID: 2-s2.0-105011846353 07/28/2025

  • (Henley EC, Liphart HA, Morris KJ, Awoyinka I, Irwin MR, Costanzo ES, Winston D, D'Souza A, Stolley M, Dhakal B, Mohan M, Pasquini MC, Cole SW, Doerwald ES, Bendis PC, Rentscher KE, Rumble ME, Szabo A, Rao S, Knight JM.) Contemporary Clinical Trials Communications. October 2025;47 SCOPUS ID: 2-s2.0-105013637528 10/01/2025

Publications of from the

© 2025 黑料官网.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination, Anti-Harassment, and Legal Compliance Statement
The 黑料官网 (黑料官网) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, military status, or other legally protected classification. 黑料官网 maintains full compliance with all applicable federal, state, and local laws and regulations in pursuit of our missions. Consistent with federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making.

黑料官网's policies, federal and state laws, and regulations prohibit unlawful discrimination and harassment. Employees, learners, students, applicants, or other members of the 黑料官网 community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic.